SEATTLE, July 3, 2013 – Greg Foltz, M.D., director of the Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute (Ivy Center), passed away from Stage IV pancreatic cancer on Thursday, June 27. Dr. Foltz, who was 50 years old, spent the last 20 years as a pioneer and champion for advancing brain cancer research in the hope of one day finding a cure.
Dr. Foltz is best known for founding the Ivy Center, the first-ever advanced brain tumor treatment center in the Pacific Northwest. As director of the Ivy Center, he played a fundamental role in establishing research collaborations and alliances among the many premier research and biotech institutions in the Pacific Northwest. Dr. Foltz also helped create the Seattle Brain Cancer Walk to raise critical funds to further support brain cancer research. Since its inception in 2008, the Walk has grown from raising $120,000 in its first year to raising nearly $1 million in 2012. This year’s annual Walk will be held on Saturday, Sept. 21, 2013. More information can be found at braincancerwalk.org.
Dr. Foltz has been a constant source of inspiration and hope to his many colleagues, partners and patients. The Seattle Times, KING 5 Evening Magazine, KIRO Radio, KOMONews.com, among others have paid a special tribute to Dr. Foltz this week.
In addition, in his honor:
- Donations may be made to The Greg Foltz, M.D. Endowed Directorship at the Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment by calling 206-386-3527 or by clicking here.
- A celebration of life event is being held this month at Benaroya Hall.
Charles Cobbs, M.D., a national expert in brain cancer treatment and research, will join Swedish on Aug. 1, 2013 as the chief neurosurgeon at the Ivy Center. He was hand-picked by Dr. Foltz to be his successor. Swedish, in partnership with Dr. Cobbs, the talented Ivy Center research team, the Ben & Catherine Ivy Foundation, along with other Ivy Center partners and supporters, is dedicated to ensuring the Ivy Center will continue its focus on advancing brain cancer research and treatment options for years to come.